News

United States Antimony's Upcoming Earnings: What to Expect

United States Antimony's Upcoming Earnings: What to Expect

United States Antimony's Earnings Forecast Overview

United States Antimony (AMEX: UAMY) is set to release its quarterly earnings report soon, sparking interest among investors. This announcement is pivotal as it provides insights into the company's financial trajectory. As anticipation builds, let's delve into what to expect from this earnings release.

Analyst Predictions for Earnings Per Share

Experts forecast that United States Antimony will report an earnings per share (EPS) of $0.01. This projection indicates cautious optimism about the company’s profitability and its ability to meet shareholder expectations.

Importance of Upcoming Earnings Announcement

The upcoming earnings announcement is critical for shareholders and potential investors. News of surpassing earnings estimates would likely boost market confidence, while any disappointing results may lead to volatility in share prices.

Past Earnings Performance

Looking back, the company's last quarter saw an EPS that missed predictions by $0.03. Despite this setback, the share price increased by 4.97% following the announcement, indicating resilience and possible investor confidence.

Overview of Recent Stock Performance

As of the latest trading session, shares of United States Antimony were priced at $7.67. Over the past year, stock performance has surged significantly, reflecting an impressive gain of 1176.23%. This upward trend could suggest a positive outlook from long-term investors.

Market Sentiments on United States Antimony

Investor sentiment plays a vital role in stock performance. The consensus among analysts gives United States Antimony a "Buy" rating based on three reviews. With a one-year price target set at $6.0, analysts note a potential downside of 21.77%—a point of concern.

Comparing Analyst Ratings with Industry Peers

When evaluating United States Antimony's standing within the industry, it’s essential to compare with similar companies:

  • Lithium Americas shows a neutral outlook, with a one-year price target of $5.71, indicating a possible 25.55% decline.
  • Nexa Res also holds a neutral stance, with a target of $6.2, suggesting a downside of 19.17%.
  • Conversely, Compass Minerals International is rated as underperforming, with a target of $18.0, reflecting a substantial potential upside of 134.68%.

Comprehensive Peer Analysis

Analyzing key financial metrics, United States Antimony has its strengths and weaknesses:

CompanyConsensusRevenue GrowthGross ProfitReturn on Equity
United States AntimonyBuy187.34%$2.84M0.51%
Lithium AmericasNeutral0.00%$-10K-2.00%
Nexa ResNeutral7.62%$153.96M7.43%
Compass Minerals InternationalUnderperform5.77%$41.20M-6.99%

Conclusions from Peer Comparisons

United States Antimony's ranking in terms of revenue growth and gross profit falls below that of competitors, though it maintains a middle-tier position for return on equity. This presents an opportunity to evaluate its operational effectiveness.

Diving Deeper into United States Antimony

United States Antimony Corp is an integrated mining company engaged in the mining, transportation, milling, smelting, and selling of minerals. Their operations span two main segments: antimony and zeolite products. Notably, the bulk of their revenue is derived from operations in the United States.

Financial Performance at a Glance

Market Capitalization: Currently, the company's market capitalization lags behind industry norms, which could signal growth opportunities or operational hurdles.

Remarkable Revenue Increase: A significant highlight is that as of the mid-year, the company achieved a remarkable 187.34% revenue growth rate. This upswing demonstrates an impressive ability to enhance top-line earnings relative to industry averages.

Profitability Metrics: The net margin is commendable, showcasing strong control over operational costs with a 1.71% net margin. However, the 0.51% return on equity indicates ongoing challenges in maximizing capital returns.

Managing Debt Effectively: The company also benefits from a favorable debt-to-equity ratio of 0.03, suggesting a lower dependence on debt to finance its operations, which instills confidence among investors.

Frequently Asked Questions

What is the expected EPS for United States Antimony?

The expected EPS for United States Antimony is forecasted to be $0.01.

How did the last earnings report impact share prices?

Last quarter's EPS missed expectations, yet shares saw a 4.97% increase following the results, indicating market resilience.

What is the current stock price of United States Antimony?

The current trading price for United States Antimony is $7.67.

How do analyst ratings compare among peers?

United States Antimony has a "Buy" rating, while several peers have either neutral or underperforming ratings.

What is the company's main product focus?

United States Antimony primarily focuses on mining, transportation, milling, and smelting of antimony and zeolite products.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 184

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 308

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 152

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 121

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading

Top 5 Most Recently Viewed Articles

Aescape Expands into Miami with Privai Spa Partnership

Updated Category News Views 160

Aescape Expands into Miami with Privai Spa Partnership In a thrilling development for luxury wellness, Aescape, known for its automated massage innovations, has teamed up with Privai Spa + Fitness to introduce its services at the famous Kimpton EPIC Hotel in Miami. This exciting collaboration features a fully customizable robotic massage experience that integrates...

Continue Reading
Debating Crypto Regulations: A Look at Elected Officials' Influence

Updated Category News Views 120

Democrats Seek Enhanced Crypto Regulations In recent discussions surrounding the cryptocurrency market structure bill, leading Democrats have expressed a clear intent to impose stricter regulations, particularly concerning stablecoin yield payments. Their aim is to mitigate any potential risks linked to elected officials’ cryptocurrency ventures. This initiative...

Continue Reading
Investors’ Chance to Lead PACS Group Inc. Securities Case

Updated Category News Views 170

Opportunity for Investors in PACS Group Inc. Investors in PACS Group Inc. (NYSE: PACS) are faced with a significant opportunity to join forces in a legal battle against alleged securities fraud. The Rosen Law Firm, recognized for its commitment to investor rights, has announced to all shareholders who acquired PACS common stock that they may now have a chance to seek...

Continue Reading
AvAir Grows Its Inventory with New Wheels and Brakes

Updated Category News Views 116

AvAir Expands Its Inventory with Lufthansa Technik Components New Inventory Includes 1,600 Wheel and Brake Assemblies AvAir, a prominent player in the aviation aftermarket sector, has significantly boosted its inventory by acquiring over 1,600 overhauled wheels and brakes from Lufthansa Technik's spare parts pool. This acquisition builds upon the long-standing...

Continue Reading
Versapay Welcomes Elizabeth Bramlage as New Marketing Leader

Updated Category News Views 323

Versapay Appoints Elizabeth Bramlage as Chief Marketing Officer Versapay has announced the appointment of Elizabeth Bramlage as the new Chief Marketing Officer, aiming to strengthen brand growth and expand its market presence. With a wealth of experience in the fintech and payments landscape, Elizabeth’s leadership will be vital in driving the company's marketing...

Continue Reading